Virtu Financial LLC bought a new stake in shares of Xencor Inc (NASDAQ:XNCR) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 21,956 shares of the biopharmaceutical company’s stock, valued at approximately $856,000.

A number of other hedge funds have also added to or reduced their stakes in XNCR. Sei Investments Co. acquired a new stake in Xencor in the second quarter worth about $138,000. Public Employees Retirement Association of Colorado increased its holdings in shares of Xencor by 64.7% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 4,404 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 1,730 shares during the period. UBS Group AG increased its holdings in Xencor by 449.9% in the first quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 4,886 shares during the last quarter. Bank of Montreal Can acquired a new position in Xencor in the second quarter worth approximately $232,000. Finally, Principal Financial Group Inc. acquired a new position in Xencor in the first quarter worth approximately $253,000. Hedge funds and other institutional investors own 82.17% of the company’s stock.

In other news, major shareholder John S. Stafford III sold 1,000 shares of the stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $48.05, for a total value of $48,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul A. Foster sold 40,000 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $46.03, for a total value of $1,841,200.00. Following the completion of the sale, the insider now directly owns 44,952 shares of the company’s stock, valued at approximately $2,069,140.56. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

Several equities analysts have recently weighed in on the company. Piper Jaffray Companies reiterated an “overweight” rating on shares of Xencor in a report on Tuesday, August 7th. Canaccord Genuity upped their target price on Xencor from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Zacks Investment Research raised Xencor from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a report on Friday, August 10th. BidaskClub cut Xencor from a “buy” rating to a “hold” rating in a report on Friday, September 7th. Finally, BTIG Research began coverage on Xencor in a report on Monday, September 10th. They issued a “buy” rating and a $56.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $41.57.

Shares of XNCR stock opened at $39.41 on Wednesday. The stock has a market capitalization of $2.36 billion, a PE ratio of -37.53 and a beta of 1.79. Xencor Inc has a 1-year low of $19.89 and a 1-year high of $48.38.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.57. The company had revenue of $29.04 million during the quarter. Sell-side analysts expect that Xencor Inc will post -1.53 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/virtu-financial-llc-buys-new-position-in-xencor-inc-xncr/2662845.html.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.